Hangzhou DAC Biotechnology Co., Ltd.
PrivateLast Round
Strategic
Jun 1, 2022
Est. Valuation
$52.25M
Total Funding Raised
$322.77M
Company Overview
Hangzhou DAC Biotechnology Co., Ltd. is a biopharmaceutical company that specializes in the research, development, and production of monoclonal antibody-drug conjugates (ADCs) for the treatment of advanced cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hangzhou DAC Biotechnology Co., Ltd. Comparables
Compare Hangzhou DAC Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MediLink Therapeutics | 85% | |
| Duality Biotherapeutics Inc | 84% | |
| Kelun-Biotech | 81% |
Hangzhou DAC Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jun 1, 2022 | ||||
| Series C | May 10, 2021 | ||||
| Series C | Mar 1, 2021 | ||||
| Series B | Sep 1, 2019 | ||||
| Series A | May 1, 2017 | ||||
Pre Seed | Nov 27, 2015 |
Hangzhou DAC Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 中信金石投资有限公司 | Series C |
| ZJKF Capital Management | Pre Seed |
| Hillhouse Investment | Series C |
| CITIC Securities Company Limited | Series C |
| CITIC Securities | Series C |
| China International Capital Corporation | Series C |
| Chenling Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 96% MoM.
- Jun 1, 2022
Led by Johnson & Johnson Innovation - JJDC, Inc.
Hangzhou DAC Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hangzhou DAC Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Hangzhou DAC Biotechnology Co., Ltd. a public or private company?
Hangzhou DAC Biotechnology Co., Ltd. is a private company.
What is the current stock price of Hangzhou DAC Biotechnology Co., Ltd.?
Hangzhou DAC Biotechnology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Hangzhou DAC Biotechnology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hangzhou DAC Biotechnology Co., Ltd. worth (valuation)?
Hangzhou DAC Biotechnology Co., Ltd.'s valuation is estimated at $52.3M based on funding round data.
Can I buy Hangzhou DAC Biotechnology Co., Ltd. stock?
Hangzhou DAC Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hangzhou DAC Biotechnology Co., Ltd.'s last funding round?
Hangzhou DAC Biotechnology Co., Ltd.'s most recent funding round was Strategic on June 1, 2022.
Who are the main investors in Hangzhou DAC Biotechnology Co., Ltd.?
Key investors in Hangzhou DAC Biotechnology Co., Ltd. include Hillhouse Investment, Chenling Capital, CITIC Private Equity Funds Management, CDG Capital, Johnson & Johnson Innovation - JJDC, Inc..
Will Hangzhou DAC Biotechnology Co., Ltd. IPO soon?
No public IPO plans have been announced for Hangzhou DAC Biotechnology Co., Ltd..
How can I track Hangzhou DAC Biotechnology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Hangzhou DAC Biotechnology Co., Ltd.'s shares on secondary markets.